Skip to main content

Vasomotor Symptoms

8
Pipeline Programs
5
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
4
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
1
17B EstradiolPhase 41 trial
DVS-233 SRPhase 33 trials
Active Trials
NCT00256685Completed568Est. Jul 2005
NCT00452595CompletedEst. May 2005
NCT00421031Completed540Est. Apr 2004
+1 more trials
Bayer
BayerLEVERKUSEN, Germany
3 programs
3
0.5mg DRSP / 0.5mg E2Phase 31 trial
AngeliqPhase 31 trial
Estradiol/DRSPPhase 31 trial
Active Trials
NCT00446199Completed735Est. Nov 2008
NCT00651599Completed90Est. May 2005
NCT00356447Completed249Est. Oct 2007
Fervent Pharmaceuticals
1 program
1
FP-101Phase 21 trial
Active Trials
NCT05312567Completed105Est. Jul 2023
Prevail Therapeutics
1 program
1
RaloxifenePhase 2
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
GS1-144Phase 11 trial
Active Trials
NCT06204250Completed86Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizer17B Estradiol
Bayer0.5mg DRSP / 0.5mg E2
BayerEstradiol/DRSP
PfizerDVS-233 SR
BayerAngeliq
PfizerDVS-233 SR
PfizerDVS-233 SR
Fervent PharmaceuticalsFP-101
Syneos HealthGS1-144

Clinical Trials (9)

Total enrollment: 2,577 patients across 9 trials

NCT00472004Pfizer17B Estradiol

Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women

Start: Feb 2006Est. completion: Dec 2009204 patients
Phase 4Completed
NCT00446199Bayer0.5mg DRSP / 0.5mg E2

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

Start: Mar 2007Est. completion: Nov 2008735 patients
Phase 3Completed
NCT00356447BayerEstradiol/DRSP

Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.

Start: May 2006Est. completion: Oct 2007249 patients
Phase 3Completed
NCT00256685PfizerDVS-233 SR

Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause

Start: Sep 2004Est. completion: Jul 2005568 patients
Phase 3Completed
NCT00651599BayerAngeliq

Treatment of Vasomotor Symptoms in Korean Post Menopausal Women

Start: Jul 2004Est. completion: May 200590 patients
Phase 3Completed
NCT00452595PfizerDVS-233 SR

Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

Start: Jan 2004Est. completion: May 2005
Phase 3Completed
NCT00421031PfizerDVS-233 SR

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

Start: Dec 2003Est. completion: Apr 2004540 patients
Phase 3Completed
NCT05312567Fervent PharmaceuticalsFP-101

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Start: Mar 2021Est. completion: Jul 2023105 patients
Phase 2Completed
NCT06204250Syneos HealthGS1-144

A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

Start: Feb 2024Est. completion: Dec 202486 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.